Kay A G
Br Med J. 1976 May 22;1(6020):1266-8. doi: 10.1136/bmj.1.6020.1266.
Of 55 patients who developed blood dyscrasias attributable to gold treatment 15 with bone marrow hypoplasia died. A few of the dyscrasias, occurring in patients who had taken a low total dose of sodium aurothiomalate, may have resulted from immune hypersensitivity, but most, occurring in patients who had taken a higher total dose, were due to cumulative toxicity. All patients receiving gold treatment should undergo frequent blood counts. Any pronounced or continuing fall in the counts is a warning of toxicity, and gold treatment should be stopped. Treatment should be resumed only with caution, and in some patients already in remission lower doses may be just as effective in controlling the disease.
在55例因金制剂治疗而出现血液系统异常的患者中,15例骨髓发育不全患者死亡。少数血液系统异常发生在硫代苹果酸金钠总剂量较低的患者中,可能是免疫超敏反应所致,但大多数发生在总剂量较高的患者中,是由于累积毒性。所有接受金制剂治疗的患者都应定期进行血常规检查。任何明显或持续的血细胞计数下降都是毒性的警告,应停止金制剂治疗。仅在谨慎的情况下才可恢复治疗,对于一些已经缓解的患者,较低剂量可能同样有效地控制疾病。